The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00744081
Recruitment Status : Unknown
Verified August 2008 by Johann Wolfgang Goethe University Hospital. Recruitment status was: Recruiting
The purpose of this study is to show superiority in complete responses of combination therapy MTC plus Glivec in patients with refractory or relapsed AML compared to a historical control which was treated with MTC alone.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Refractory AML after primary therapy
First relapse after a safe previous diagnosis of de novo or secondary AML
Age > 18 years
Serum bilirubin < 2.0 mg/dl
Serum creatinine < 1.5 times the normal value or a creatinine clearance > 60 ml/min
ECG and heart echography prior to start of therapy without severe findings
Overall condition < 2 according to ECOG criteria
Life expectancy > 6 weeks
Written informed consent by patients with full legal capacity
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Topoisomerase II Inhibitors